Journal
VACCINE
Volume 28, Issue 41, Pages 6684-6691Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2010.08.007
Keywords
Bifidobacterium; Mucosal vaccine; Salmonella
Categories
Funding
- Japan Society for the Promotion of Science (JSPS) [20591201]
- Hyogo Science and Technology Association
- Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan
- KICOS [K20704000007-09A0500-00710]
- Grants-in-Aid for Scientific Research [20591201] Funding Source: KAKEN
Ask authors/readers for more resources
We developed a novel vaccine platform utilizing Bifidobacterium as an antigen delivery vehicle for mucosal immunization. Genetically modified Bifidobacterium longum displaying Salmonella-flagellin on the cell surface was constructed for the oral typhoid vaccine. The efficiency of this vaccine was evaluated in a murine model of typhoid fever. We then orally administered 2.5 x 10(7) CFU of the recombinant Bifidobacterium longum (vaccine) or parental Bifidobacterium longum, or PBS to BALB/C mice every other day for 2 weeks. After the administration, a total of 42 mice (14 mice in each group) were challenged with Salmonella Typhimurium (1.0 x 10(7) CFU/mouse). While 12 mice in the PBS group, and 9 in the parental Bifidobacterium longum group died (median survival: 14 and 25 days), only two in the vaccine group died. These data support that our genetically modified Bifidobacterium antigen delivery system offers a promising vaccine platform for inducing efficient mucosal immunity. (C) 2010 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available